Creation of the Swiss Institute for Vaccine Research in Lausanne, Switzerland



    LAUSANNE, SWITZERLAND, December 5 /CNW/ - The Swiss Institute for Vaccine
Research will be launched on December 5, 2007, in Lausanne, Switzerland. The
new Institute will encompass the principal aspects of vaccine research to
fight the three main infectious diseases : HIV/AIDS, tuberculosis and malaria.
The Institute will also benefit from ongoing vaccine research in cancer and
influenza.

    The Institute will develop an immunology, microbiology and vaccine
research laboratory platform to encourage cooperation between scientists
working in the field of HIV, malaria, tuberculosis, influenza and cancer
vaccine development in Switzerland, from fundamental to clinical researchers.
Vaccines against hepatitis C, Dengue fever and other infectious agents may be
developed at a later date.

    The Institute will initially be based on a partnership between the
following Swiss institutions:

    --  The Centre Hospitalier Universitaire Vaudois (CHUV) and the Faculty
of Biology and Medicine (FBM) of the University of Lausanne (UNIL),

    --  the Ecole Polytechnique Federale de Lausanne (EPFL),

    --  the Institute for Biomedical Research in Bellinzona (IRB),

    --  and the Ludwig Institute for Cancer Research, Lausanne branch in
Epalinges (LICR).

    These four institutions have a strong tradition in the fields of
immunology, virology, and vaccines against HIV/AIDS, malaria, tuberculosis and
cancer. The new Institute will further seek collaboration with other Swiss
institutions.

    The new Institute also aims to train new generations of scientists in the
field of vaccines, by creating several new research groups. The Institute will
work with the most prominent public and private organizations involved in
vaccine development and will also encourage cooperation with industrial
partners.

    The role of each partner

    The Swiss Institute for Vaccine Research will initially be based on four
partner institutions, selected for their scientific competence and clinical or
laboratory infrastructures.

    The CHUV will conduct the translational and immunology programmes for the
evaluation of immune responses induced by a vaccine. The CHUV will also make
available its clinical trial infrastructure.

    The EPFL will conduct the fundamental research programme in virology,
microbiology and vectorology. The ease of access to robotics and microtechnics
will be of prime importance for the development of new high flow and automated
immunology tests. The EPFL will also make available the infrastructures for
proteomics, microscopic and biomedical imaging, protein production, genomics,
and high flow biomolecular screening.

    The IRB will conduct the fundamental research programme in immunology
with, as its main objective, the characterization of T cell memory and the
study of the mechanisms causing T cell responses.

    The LICR will conduct a fundamental research programme in immunology
aimed at characterizing specific tumour responses generated by vaccination.

    The launch

    The launch of the Swiss Institute for Vaccine Research will take place on
December 5, 2007, at 17 :00 CET, in Lausanne, Switzerland, in the presence of
the Swiss Secretary of State for Education and Research, Charles Kleiber,
representatives of the Bill & Melinda Gates Foundation and the World Health
Organization (WHO) as well as leading US specialists in HIV/AIDS research.




For further information:

For further information: Genevensis Healthcare Communications for Swiss
Institute for Vaccine Research Daniele Letore-Castle Tel. +41 22 779 0620 Mob:
+41 79 202 6667 Mail: info@genevensis.com

Organization Profile

SWISS INSTITUTE FOR VACCINE RESEARCH

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890